球囊肺动脉成形术治疗不可手术慢性血栓栓塞性肺动脉高压的德国初始经验
该前瞻性研究纳入56例不可手术慢性血栓栓塞性肺动脉高压患者,共行266次球囊肺动脉成形术(BPA)。BPA改善了WHO功能分级、6分钟步行距离(平均变化+33 m)、右心室功能及血流动力学,平均肺动脉压下降18%、肺血管阻力下降26%。操作相关不良事件发生率为9.4%,最常见为肺血管损伤及继发肺出血,多数无症状且自限,但1例死于肺出血,死亡率为1.8%。
要点
- BPA可改善不可手术CTEPH患者的血流动力学与临床指标。
- 操作相关不良事件发生率为9.4%,主要为肺血管损伤和肺出血。
- 1例死于肺出血,死亡率为1.8%,需权衡风险获益。
核心结论
- BPA可带来血流动力学和临床改善,但相关并发症数量可观,包括1例致命性肺出血。
- BPA对生存的影响尚不清楚,需开展随机对照结局试验与已批准药物治疗比较以评估风险获益。
研究设计与样本
- 前瞻性系列研究,纳入56例连续不可手术CTEPH患者。
- 在两家德国机构共行266次BPA介入(每例中位数5次)。
- 所有患者基线及末次介入后24周接受包括右心导管在内的全面诊断评估。
主要发现
- BPA改善WHO功能分级、6分钟步行距离(平均变化+33 m)、右心室功能和血流动力学。
- 平均肺动脉压下降18%,肺血管阻力下降26%。
- 操作相关不良事件发生于9.4%的介入操作,最常见为肺血管损伤及继发肺出血。
- 多数不良事件无症状且自限,1例患者死于肺出血,死亡率为1.8%。
临床怎么用
- 对不可手术CTEPH患者,BPA可考虑用于改善血流动力学和临床状态。
- 开展BPA需警惕肺血管损伤和肺出血风险,并做好并发症管理。
- 因生存获益未知,应与患者充分沟通风险获益并考虑随机对照试验证据需求。
局限性
- BPA对生存的影响未知。
- 需随机对照结局试验与已批准药物治疗比较以进行适当风险获益评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Balloon pulmonary angioplasty (BPA) is an emerging treatment for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).We report on a prospective series of 56 consecutive patients who underwent 266 BPA interventions (median, five per patient) at two German institutions. All patients underwent a comprehensive diagnostic work-up including right heart catheterisation at baseline and 24 weeks after their last intervention.BPA resulted in improvements in WHO functional class, 6 min walk distance (mean change, +33 m), right ventricular function and haemodynamics, including a decline in mean pulmonary artery pressure by 18% and in pulmonary vascular resistance by 26%. Procedure-related adverse events occurred in 9.4% of the interventions. The most common complications were related to pulmonary vascular injury and consecutive pulmonary bleeding. Most of these events were asymptomatic and self-limiting, but one patient died from pulmonary bleeding, resulting in a mortality rate of 1.8%.BPA resulted in haemodynamic and clinical improvements but was also associated with a considerable number of complications, including one fatal pulmonary bleeding. As the effects of BPA on survival are unknown, randomised controlled outcome trials comparing BPA with approved medical therapies in patients with inoperable CTEPH are required to allow for appropriate risk-benefit assessments.
引用
- Olsson KM, Wiedenroth CB, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J. 2017. PMID: 28596435. doi:10.1183/13993003.02409-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。